Blood test could predict which melanoma patients benefit from immunotherapy
NCT ID NCT05105100
Summary
This study aimed to understand why some patients with advanced melanoma respond to immunotherapy while others don't. Researchers analyzed blood samples from 25 patients receiving standard pembrolizumab treatment to identify immune cell patterns linked to treatment success. The goal was to find blood-based markers that could predict patient outcomes without changing their treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.